Skip to main content
Article
Advances in neurotrophic factor and cell-based therapies for Parkinson's disease: A mini-review
Gerontology
  • Michael D. Staudt, Schulich School of Medicine & Dentistry
  • Andrea R. Di Sebastiano, Schulich School of Medicine & Dentistry
  • Hu Xu, Schulich School of Medicine & Dentistry
  • Mandar Jog, Schulich School of Medicine & Dentistry
  • Susanne Schmid, Schulich School of Medicine & Dentistry
  • Paula Foster, Schulich School of Medicine & Dentistry
  • Matthew O. Hebb, Schulich School of Medicine & Dentistry
Document Type
Article
Publication Date
4-1-2016
URL with Digital Object Identifier
10.1159/000438701
Abstract

Parkinson's disease (PD) affects an estimated 7-10 million people worldwide and remains without definitive or disease-modifying treatment. There have been many recent developments in cell-based therapy (CBT) to replace lost circuitry and provide chronic biological sources of therapeutic agents to the PD-affected brain. Early neural transplantation studies underscored the challenges of immune compatibility, graft integration and the need for renewable, autologous graft sources. Neurotrophic factors (NTFs) offer a potential class of cytoprotective pharmacotherapeutics that may complement dopamine (DA) replacement and CBT strategies in PD. Chronic NTF delivery may be an integral goal of CBT, with grafts consisting of autologous drug-producing (e.g., DA, NTF) cells that are capable of integration and function in the host brain. In this mini-review, we outline the past experience and recent advances in NTF technology and CBT as promising and integrated approaches for the treatment of PD.

Citation Information
Michael D. Staudt, Andrea R. Di Sebastiano, Hu Xu, Mandar Jog, et al.. "Advances in neurotrophic factor and cell-based therapies for Parkinson's disease: A mini-review" Gerontology Vol. 62 Iss. 3 (2016) p. 371 - 380
Available at: http://works.bepress.com/susanne-schmid/18/